# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Samuel Johnson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN008-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Catriona Bell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week depression review. **S**

## History of present illness

Mr. Johnson returns six weeks after starting sertraline 50 mg. He is a little better: he has written letters, though not his book, and walked out with a friend twice. He still wakes in the early morning with dread and reproaches himself for idleness. He has had five psychotherapy sessions and the first two sessions of behavioral therapy for tics, in which he is learning to notice the urge before the head-shaking tic and to answer it with a competing movement. He has no side effects. **S**

| Element | Detail |
|---|---|
| Sertraline | 50 mg daily for six weeks |
| Mood | PHQ-9 15; GAD-7 9 |
| Psychotherapy | Five sessions |
| Tic therapy | Two sessions |
| Side effects | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight change or sweats |
| Neurological | Positive | Tics as before |
| Psychiatric | Positive | Mood a little better; early waking; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 98.2 kg; BMI 29.3 kg/m². All vital signs are synthetic.

PHQ-9: 15; GAD-7: 9. All results are synthetic.

## Change since baseline

- PHQ-9: 21 at baseline, 15 at this visit **S**
- GAD-7: 12 at baseline, 9 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Better groomed; blood pressure 124/78, pulse 78 |
| Neurological | Tics as described at the consultation |
| Psychiatric | Less slowed; reactive affect |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, severe** (F33.2). Partial response at six weeks: PHQ-9 15 from 21, a 29% fall, short of the 50% that defines response. Tolerating sertraline. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Increase sertraline to 100 mg daily.
   - Continue weekly psychotherapy.
   - Review in five weeks.
2. **Tourette syndrome** (F95.2). Behavioral therapy for tics under way. **S**
   - Continue the eight sessions.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Depression measure (PHQ-9) | At baseline and at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 15, from 21: partial response |
| Medication safety | Sertraline adherence and adverse effects | Every visit in the acute phase; reassess at 2 weeks after starting and after each dose change | Completed today | No side effects; increased to 100 mg |
| Survey | Suicide-risk review (PHQ-9 item 9 and structured questions since the last visit), safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm |
| Referral | Psychotherapy (cognitive behavioral therapy with behavioral activation) | Offer to all with moderate or severe depression | Completed today | Five sessions |
| Survey | Anxiety measure (GAD-7) | At baseline and with PHQ-9 reviews | Completed today | 9, from 12 |
| Survey | Tic severity (Yale Global Tic Severity Scale, recorded in the note; no LOINC code is used) | At diagnosis and periodically to judge the need for and response to treatment | Due | At three months |
| Referral | Comprehensive Behavioral Intervention for Tics | Offer as an initial treatment option | Completed today | Two of eight sessions |
| Medication safety | Tic-suppressing medication (alpha-2 agonist, aripiprazole, or other) | When tics cause impairment that behavioral therapy does not relieve | Not indicated | Not needed |

## Goal progress

- PHQ-9 response (at least a 50% fall) by three months and remission (below 5) by six months. In progress; target 2026-09-28. **S**
- Back at daily writing and seeing friends again by three months. In progress; target 2026-06-22. **S**
- Fewer and less disruptive tics, judged by him and by the tic severity scale, by six months. In progress; target 2026-09-28. **S**
- Safety plan in place and reviewed at every visit. In progress; target 2026-09-28. **S**

## Medication changes

- Stopped: Sertraline 50 mg oral tablet, one tablet by mouth once daily **S**
- Started: Sertraline 100 mg oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim T, et al. Neurology 2019;92(19):896-906) (2019), American Academy of Neurology
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Review in five weeks. Psychotherapy weekly; tic therapy weekly. **S**
- Next scheduled visit 2026-06-22: eleven-week review of depression and tics. **S**
